Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 7, 2012, Pages 1076-1079

  Tovar, Natalia ^a   Fernández de Larrea, Carlos ^a   Elena, Montserrat ^a   Cibeira, M Teresa ^a   Aróstegui, Juan I ^a   Rosiñol, Laura ^a   Filella, Xavier ^a   Yagüe, Jordi ^a   Bladé, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Immune recovery; Isotype; Plasma cell dyscrasia; Residual disease

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A KAPPA CHAIN; IMMUNOGLOBULIN A LAMBDA CHAIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M KAPPA CHAIN; IMMUNOGLOBULIN M LAMBDA CHAIN; MELPHALAN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84862139610     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.03.004     Document Type: Article

References (16)

1. Bladé J., Samson D., Reece D., et al. Myeloma Subcommittee of the European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998, 102:1115-1123.
2. Durie B.G., Harousseau J.L., Miguel J.S., et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
3. Kapoor P., Kumar S., Dispenzieri A., et al. Survival outcomes of patients with multiple myeloma (MM) achieving stringent complete response (sCR) following upfront autologous stem cell transplantation (SCT) [abstract]. J Clin Oncol 2011, 29(Suppl 15). abstract 8069.
4. Paiva B., Martinez-Lopez J., Vidriales M.B., et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011, 29:1627-1633.
5. Fernández de Larrea C., Tovar N., Cibeira M.T., et al. Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica 2011, 96:171-173.
6. Fernández de Larrea C., Cibeira M.T., Elena M., et al. Abnormal serum free light chain in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 2009, 114:4954-4956.
7. Dispenzieri A., Kyle R., Merlini G., et al. International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23:215-224.
8. Bradwell A.R. Analysis of immunoglobulin heavy chain/light chain pairs (Hevylite). Serum Free Light Chain Analysis (Plus Hevylite) 2010, 301-319. Binding Site, Birmingham, U.K.
9. Chronic Leukemia-Myeloma Task Force, National Cancer Institute. Proposed guidelines for protocol studies, II: plasma cell myeloma. Cancer Chemother Rep 3 1968, 1:17-39.
10. Nadal E., Giné E., Bladé J., et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004, 33:61-64.
11. Bladé J., Rosiñol L. Changing paradigms in the treatment of multiple myeloma. Haematologica 2009, 94:163-165.
12. Paiva B., Vidriales M.B., Cerveró J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
13. Avet-Loiseau H., Harousseau J.L., Moreau P., et al. Heavy/light chain-specific immunoglobulin ratios at presentation are prognostic for progression-free survival in the IFM 2005-01 Myeloma Trial [abstract]. Blood 2009, 114. abstract 1818.
14. Katzmann J., Clark R., Dispenzieri A., et al. Isotype-specific heavy/light chain suppression as a predictor of myeloma development in monoclonal gammopathy of undetermined significance [abstract]. Blood 2009, 114. abstract 1788.
15. Zent C.S., Wilson C.S., Tricot G., et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998, 91:3518-3523.
16. Mark T., Jayabalan D., Coleman M., et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol 2008, 143:654-660.